AU2023229972A1 - TGF-β ANTIBODIES - Google Patents

TGF-β ANTIBODIES Download PDF

Info

Publication number
AU2023229972A1
AU2023229972A1 AU2023229972A AU2023229972A AU2023229972A1 AU 2023229972 A1 AU2023229972 A1 AU 2023229972A1 AU 2023229972 A AU2023229972 A AU 2023229972A AU 2023229972 A AU2023229972 A AU 2023229972A AU 2023229972 A1 AU2023229972 A1 AU 2023229972A1
Authority
AU
Australia
Prior art keywords
seq
tgf
antibody
amino acid
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023229972A
Other languages
English (en)
Inventor
Gitte DE BOECK
Fanny Lambert
Stéphanie LIENART
Sophie Lucas
Lore Mariën
Sebastian Paul VAN DER WONING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Publication of AU2023229972A1 publication Critical patent/AU2023229972A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2023229972A 2022-03-09 2023-03-09 TGF-β ANTIBODIES Pending AU2023229972A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2203269.2A GB202203269D0 (en) 2022-03-09 2022-03-09 TGF-Beta antibodies
GB2203269.2 2022-03-09
PCT/EP2023/056082 WO2023170241A1 (en) 2022-03-09 2023-03-09 TGF-β ANTIBODIES

Publications (1)

Publication Number Publication Date
AU2023229972A1 true AU2023229972A1 (en) 2024-09-12

Family

ID=81175458

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023229972A Pending AU2023229972A1 (en) 2022-03-09 2023-03-09 TGF-β ANTIBODIES

Country Status (9)

Country Link
US (1) US20250188161A1 (https=)
EP (1) EP4490186A1 (https=)
JP (1) JP2025508073A (https=)
CN (1) CN119173533A (https=)
AU (1) AU2023229972A1 (https=)
CA (1) CA3245104A1 (https=)
GB (1) GB202203269D0 (https=)
IL (1) IL315033A (https=)
WO (2) WO2023170241A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
ES2860952T3 (es) 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
EP3139957A4 (en) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
AU2018387829B2 (en) 2017-12-22 2024-12-19 Argenx Bvba Bispecific antigen binding construct

Also Published As

Publication number Publication date
EP4490186A1 (en) 2025-01-15
WO2023170242A1 (en) 2023-09-14
JP2025508073A (ja) 2025-03-21
IL315033A (en) 2024-10-01
WO2023170241A1 (en) 2023-09-14
GB202203269D0 (en) 2022-04-20
CN119173533A (zh) 2024-12-20
CA3245104A1 (en) 2023-09-14
US20250188161A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
US11242404B2 (en) Antibodies against signal-regulatory protein alpha and methods of use
US20230212308A1 (en) Antibodies binding to gprc5d
US20220411491A1 (en) Antibodies binding to gprc5d
US20240067734A1 (en) Antibodies binding to NKG2D
US12098213B2 (en) Antibodies binding to HLA-A2/WT1
EP3746476A1 (en) Anti-ms4a4a antibodies and methods of use thereof
JP2023548034A (ja) デルタ様リガンド３（ｄｌｌ３）抗原結合ドメインを含むタンパク質及びその使用
CN116234826A (zh) Btla抗体
US20250188161A1 (en) TGF-ß ANTIBODIES
JPWO2017170597A1 (ja) 血中でハプトグロビンに結合して多価の免疫複合体を形成する抗体を有効成分とする自己免疫疾患治療剤
EP4118116A1 (en) Musk agonist antibody
CN121969650A (zh) Ror1抗体的糖工程化形式和使用方法
WO2025067469A1 (zh) Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
AU2024261382A1 (en) Molecules for modulating the immune system and uses thereof
JP2024510200A (ja) 自己免疫治療用途のためのｃｄ７９ｂ抗体の使用
HK40061355A (en) Antibodies binding to gprc5d
HK40009608B (zh) 针对信号调控蛋白α的抗体和使用方法
EA045372B1 (ru) Анти-tigit антитела